Galera Therapeutics (NASDAQ:GRTX) Research Coverage Started at Credit Suisse Group

Share on StockTwits

Credit Suisse Group began coverage on shares of Galera Therapeutics (NASDAQ:GRTX) in a research note released on Monday morning, Benzinga reports. The brokerage issued a neutral rating and a $14.00 price objective on the stock.

Several other research firms have also recently commented on GRTX. Bank of America began coverage on Galera Therapeutics in a report on Monday. They issued a buy rating and a $15.00 price target for the company. Citigroup began coverage on Galera Therapeutics in a report on Monday. They issued a buy rating and a $20.00 price target for the company.

GRTX opened at $12.07 on Monday. Galera Therapeutics has a 12 month low of $11.50 and a 12 month high of $14.88.

In other news, major shareholder Enterprise Associates 14 New acquired 416,666 shares of Galera Therapeutics stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average cost of $11.79 per share, with a total value of $4,912,492.14. Also, insider Holdings A/S Novo acquired 500,000 shares of Galera Therapeutics stock in a transaction that occurred on Tuesday, November 12th. The shares were purchased at an average cost of $12.76 per share, with a total value of $6,380,000.00.

Galera Therapeutics Company Profile

Galera Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis.

Read More: What is a short straddle?

Receive News & Ratings for Galera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.